Breaking Finance News

West Pharmaceutical (NYSE:WST) has been downgraded from Buy to Neutral in a statement by Bank of America (Merrill Lynch) earlier today.

Boasting a price of $94.18, West Pharmaceutical (NYSE:WST) traded -4.27% lower on the day. With the last stock price up 0.10% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. WST has recorded a 50-day average of $92.70 and a two hundred day average of $91.36. Trade Volume was up over the average, with 556,844 shares of WST changing hands over the typical 392,197

Bank of America (Merrill Lynch) has downgraded West Pharmaceutical (NYSE:WST) from Buy to Neutral in a statement released on 10/17/2017.

See Chart Below

West Pharmaceutical (NYSE:WST)

West Pharmaceutical has a 52 week low of $70.17 and a 52 week high of $99.91 with a P/E ratio of 39.25 The company’s market cap is currently $0.

In addition to Bank of America (Merrill Lynch) reporting its target price, a total of 4 brokers have issued a research note on the company. The average stock price target is $66.00 with 2 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On West Pharmaceutical (NYSE:WST)

West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.